Chronic Lymphocytic Leukemia

>

Latest News

Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL

March 15th 2024

In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.

FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL
FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL

March 15th 2024

Zanubrutinib Improves Survival, Response in Patients With CLL
Zanubrutinib Improves Survival, Response in Patients With CLL

March 7th 2024

Investigating Beyond the First-Generation BTK Inhibitors in CLL
Investigating Beyond the First-Generation BTK Inhibitors in CLL

March 5th 2024

Deep and Durable Remissions With Liso-cel in Relapsed/Refractory CLL/SLL
Deep and Durable Remissions With Liso-cel in Relapsed/Refractory CLL/SLL

February 23rd 2024

Video Series
Video Interviews
Podcasts

More News